Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zygote arrest protein 1 (ZAR1) is an oocyte-specific, maternal-effect RNA-binding protein containing a zinc finger domain, necessary for the transition from oocyte to embryo in mammals[1][3]. ZAR1 mediates the formation of membraneless ribonucleoprotein compartments (MARDOs) that store maternal mRNAs in oocytes, repressing their translation until the appropriate developmental stage[3]. ZAR1 ensures that maternal mRNAs are properly stored, translated, or degraded, facilitating successful embryonic development after fertilization. Loss of function in ZAR1 leads to female infertility: oocytes and early fertilization appear normal, but embryos arrest at the one-cell stage due to defective maternal mRNA handling, with rare progression to the two-cell stage, and complete failure to develop further[1][3][5]. ZAR1 does not serve as a known therapeutic drug target, receptor, or enzyme and is not associated with specific drugs, safety concerns, or established roles as a biomarker.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zygote arrest protein 1 (ZAR1).